Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: April 16, 2025
Context: This filing incorporates by reference a press release (Exhibit 99.1) dated April 16, 2025. The document serves to update the registration statements on Form F-3 and Form S-8. The provided text contains only the cover page, incorporation by reference language, exhibit index, and signature block; it does not include the full text of the press release or financial statements.
Key Financial Metrics
The provided filing text does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not provide details on material changes versus prior periods. The specific content of the press release referenced in Exhibit 99.1 is not included in the input data.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risk factors, or details on contingencies and unusual items. The press release referenced in the exhibit is excluded from the provided text.
Investor Verification Checklist
- Review the full text of Exhibit 99.1 (Press Release dated April 16, 2025) to understand the specific event or announcement triggering this filing.
- Verify the impact of the announcement on the company's registration statements (Form F-3 and Form S-8).
- Check subsequent filings for detailed financial updates if the press release pertains to financial results.